Merck KGaA agreed to buy Bio-Techne Corporation for about $11.3 billion to bolster its life-science business, marking the German pharma and technology group’s biggest acquisition in more than a decade ...

June 25 (Reuters) - Merck KGaA has agreed to acquire biotech firm Bio-Techne Corp for $11.3 billion, the German science and healthcare firm said in a statement on Thursday. Shares of Bio-Techne rose ...

Germany’s Merck KGaA will buy Bio-Techne Corp. in a deal worth $11.3 billion, one of the largest acquisitions in Minnesota history. The sale follows investor pressure on Minneapolis-based Bio-Techne, ...

Q1 beat and Bio-Techne deal drive upside, but valuation looks full. Read here for a detailed investment analysis.

On June 25, 2026, investors tracked deal progress as Bio-Techne shares responded to the proposed buyout terms.

Merck KGaA has agreed to acquire Bio-Techne (NasdaqGS:TECH) for $11.5b in an all cash deal. Bio-Techne's board has unanimously approved the transaction, which is now subject to regulatory review. The ...

German drugmaker Merck ​KGaA said on Thursday it will acquire U.S. biotech firm Bio-Techne for $11.3 billion, its largest deal in over a decade.

Detailed price information for Bio-Techne Corp (TECH-Q) from The Globe and Mail including charting and trades.

Merck enters into definitive agreement to acquire Bio-Techne for $11.3 billion: Darmstadt, Germany Saturday, June 27, 2026, 12:00 Hrs [IST] Merck, a leading science and technology ...

Gemini Bioproducts announced the acquisition of selected fetal bovine serum product rights and inventory from Bio-Techne (TECH). GeminiBio has a 39-year history of supporting FBS customers. With this ...

Germany’s Merck KGaA has announced a major acquisition agreement to buy U.S.-based life sciences company Bio-Techne Corp (NASDAQ:TECH) in a deal valued at approximately $11.3 billion, marking one of ...